Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 56.86m |
Free float | 56.84m |
P/E (TTM) | -- |
Market cap | 274.08m USD |
EPS (TTM) | -2.52 USD |
--
More ▼
Announcements
- Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
- Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
- Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
- Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
- Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
- Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
- Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
- Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
More ▼